Michael J. Mauro

2 weeks ago | nature.com | Andreas Hochhaus |Dong-Wook Kim |Jorge Cortés |Koji Sasaki |Michael J. Mauro |Timothy Hughes | +7 more

AbstractAsciminib is the first approved BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP). The present final analysis of the phase 1, open-label, nonrandomized trial (NCT02081378) assessed the long-term safety, tolerability, and antileukemic activity of asciminib in 115 patients with chronic myeloid leukemia in chronic phase without the BCR::ABL1T315I mutation who received asciminib 10–200 mg twice daily (BID) or 80–200 mg once daily (cutoff: March 14, 2023).

Sep 27, 2024 | targetedonc.com | Michael J. Mauro

Michael J. Mauro, MD, director of the chronic myeloid leukemia (CML) program in the leukemia service at Memorial Sloan Kettering Cancer Center, discusses decision-making for patients with chronic myeloid leukemia (CML). CML is a complex disease and according to Mauro, decision-making often depends on the stage at diagnosis.

Sep 7, 2024 | targetedonc.com | Michael J. Mauro

Michael J. Mauro, MD, director of the chronic myeloid leukemia (CML) program in the leukemia service at Memorial Sloan Kettering Cancer Center, provides a summary of a presentation at the 2024 Society of Hematologic Oncology (SOHO) Annual Meeting on the recent advancements in CML treatment and applying clinical evidence to cases that are advanced.

May 16, 2024 | nature.com | Jorge Cortés |Koji Sasaki |Timothy Hughes |Michael J. Mauro |Andreas Hochhaus |Michael C. Heinrich | +5 more

AbstractAsciminib targets the BCR::ABL1 myristoyl pocket, maintaining activity against BCR::ABL1T315I, which is resistant to most approved adenosine triphosphate–competitive tyrosine kinase inhibitors. We report updated phase I results (NCT02081378) assessing safety/tolerability and antileukemic activity of asciminib monotherapy 200 mg twice daily in 48 heavily pretreated patients with T315I-mutated chronic-phase chronic myeloid leukemia (CML-CP; data cutoff: January 6, 2021).

Oct 24, 2023 | medscape.com | Michael J. Mauro |Jane F. Apperley

Authors and Disclosures Michael J. Mauro, MD Professor of Medicine, Weill Cornell Medicine; Director, CML Program, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NYDisclosure: Michael J. Mauro, MD, has disclosed the following relevant financial relationships:Serve(d) as a consultant for: Novartis; Bristol Myers Squibb; Pfizer; Takeda; AbbVieReceived research grant from: Novartis; Bristol Myers Squibb; Takeda; Sun Pharma Jane F.